A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Open Label ◽

Open Label Study ◽

Label Study ◽

Interleukin 17A

Faculty Opinions recommendation of A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718882523.793500240 ◽

2014 ◽

Author(s):

Luigi Naldi

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Interleukin 17A

Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study

The Journal of Dermatology ◽

10.1111/1346-8138.14294 ◽

2018 ◽

Vol 45 (5) ◽

pp. 529-539 ◽

Cited By ~ 26

Author(s):

Shigetoshi Sano ◽

Hiroshi Kubo ◽

Hitomi Morishima ◽

Ryosuke Goto ◽

Richuan Zheng ◽

...

Keyword(s):

Monoclonal Antibody ◽

Japanese Patients ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Generalized Pustular Psoriasis ◽

Erythrodermic Psoriasis ◽

Interleukin 23

Effectiveness of weekly azathioprine pulse in the treatment of chronic plaque psoriasis: an open-label study

Clinical and Experimental Dermatology ◽

10.1111/ced.12887 ◽

2016 ◽

Vol 41 (7) ◽

pp. 717-722 ◽

Cited By ~ 2

Author(s):

P. Verma ◽

K. K. Verma ◽

N. Khanna ◽

S. Gupta ◽

N. Bhari

Keyword(s):

Plaque Psoriasis ◽

Open Label ◽

Open Label Study ◽

Effectiveness of weekly azathioprine pulse in the treatment of chronic plaque psoriasis: an open-label study: reply to author

Clinical and Experimental Dermatology ◽

10.1111/ced.13193 ◽

2017 ◽

Vol 42 (7) ◽

pp. 805-806

Author(s):

S. Sarika ◽

S. Criton

Keyword(s):

Plaque Psoriasis ◽

Open Label ◽

Open Label Study ◽

The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2011.10.020 ◽

2012 ◽

Vol 67 (4) ◽

pp. 642-650 ◽

Cited By ~ 33

Author(s):

Alice B. Gottlieb ◽

Robert E. Kalb ◽

Andrew Blauvelt ◽

Michael P. Heffernan ◽

Howard L. Sofen ◽

...

Keyword(s):

Plaque Psoriasis ◽

Inadequate Response ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Study ◽

Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.44 ◽

2021 ◽

Vol 5 (6) ◽

pp. s44

Author(s):

Linda Stein Gold ◽

Melinda Gooderham ◽

Kim Papp ◽

Laura Ferris ◽

Mark Lebwohl ◽

...

Keyword(s):

Plaque Psoriasis ◽

Adult Patients ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

N/A

An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/j.1468-3083.2005.01247.x ◽

2005 ◽

Vol 19 (5) ◽

pp. 556-563 ◽

Cited By ~ 36

Author(s):

JP Ortonne ◽

A Khemis ◽

JYM Koo ◽

J Choi

Keyword(s):

Combination Therapy ◽

Plaque Psoriasis ◽

Ultraviolet B ◽

Open Label ◽

Open Label Study ◽

A multicenter, open‐label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis

Journal of Dermatological Treatment ◽

10.1080/09546630701846103 ◽

2008 ◽

Vol 19 (3) ◽

pp. 146-155 ◽

Cited By ~ 23

Author(s):

Gerald G. Krueger ◽

Alice B. Gottlieb ◽

Wolfram Sterry ◽

Neil Korman ◽

Peter Van De Kerkhof

Keyword(s):

Plaque Psoriasis ◽

Open Label ◽

Open Label Study ◽

Faculty Opinions recommendation of Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718340215.793493941 ◽

2014 ◽

Author(s):

Kamran Ghoreschi ◽

Sebastian Volc

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Study

THE EFFICACY AND SAFETY OF ALIROCUMAB IN CHILDREN AND ADOLESCENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): PHASE 3, MULTINATIONAL OPEN-LABEL STUDY

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(21)01800-3 ◽

2021 ◽

Vol 77 (18) ◽

pp. 441

Author(s):

Eric Bruckert ◽

Sonia Caprio ◽

Albert Wiegman ◽

Min-Ji Charng ◽

Cézar A. Zárate-Morales ◽

...

Keyword(s):

Children And Adolescents ◽

Familial Hypercholesterolemia ◽

Efficacy And Safety ◽

Homozygous Familial Hypercholesterolemia ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽